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The recent availability of the carcinoembryonic
antigen (CEA) assay has stimulated great clinical interest in tumor antigens. Carcinoembryonic antigen
is not the only specific or tumor-associated antigen
currently identified . There are a number of other
tumor antigens which have been isolated, some of
which are related to CEA and some of which are
totally different. There is, for example, a nonspecific
cross-reacting antigen (NCA) which has been discovered in certain preparations which were considered
originally to be CEA. Nonspecific cross-reacting
antigen is a beta globulin (25% carbohydrate) which
cross-reacts with antibodies to CEA and may be
the nonspecific background element that causes the
CEA titer to be elevated in certain nonmalignant
diseases. There is also a membrane-associated, low
molecular weight tissular autoantigen (MT A) which
has been recently identified. However, this material
is not antigenetically related to CEA or NCA .
Carcinoembryonic antigen is an antigenetic
glycoprotein. The antibody-active site of this antigen
is actually in the glucose portion of the molecule
rather than the protein portion. Carcinoembryonic
antigen has a relatively high molecular weight
(200,000) an d is soluble in perchloric acid. The perchloric acid solubility of CEA has greatly facilitated
extraction of the antigen from tumor tissue and is
also responsible for the relative convenience of the
current method of performing the radioimmunoassay for detection of this antigen.
Carcinoembryonic antigen is present in the
This is an edited transcription of a lecture presented by Dr.
Hoffer at the Postgraduate Course in Nuclear Medicine, February
27, 1975, in Williamsburg, Virginia.
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glycocalyx of malignant gastrointestinal cells and is
also present in fetal gastrointestinal tissues during the
first and second trimesters of fetal life. Gold and
Freedman discovered and isolated this material in
1965 (I). A radioimmunoassay for its detection was
developed soon after (2). Initial results with this assay
indicated that elevated blood CEA level was a specific
test for adenocarcinoma of the colon, although occasional patients with pancreatic carcinoma also had
elevated titers. However, more extensive clinical
studies indicate that circulating CEA is not only present in colonic and pancreatic malignancies but in
other malignancies as well, as noted by H . J. Hansen,
MD (oral communication, April , 1973). Unfortunately, CEA is also present in certain nonmalignant
disorders and some normal patients. the common
denominator in most cases of elevated CEA level associated with bowel disease is rapid cellular proliferation with disruption of the basement membrane. The
disruption of the basement membrane is important
because the antigen must leak into the circulation in
order to be detected. The cellular proliferation may
be responsible for the cell surface exposure of certain
primitive antigens that are not normally found in
adult huma n tissues . The upper limit of normal for
the currently available CEA assay is approximately
2.5 ng/ ml. However, a finite percentage of normal individuals will have CEA levels above this value.
Three percent of healthy, young nonsmoking
volunteers and 19% of smokers have CEA levels over
2.5 ng/ ml. There is some question as to whether the
smokers who do have elevated titers are not in fact
candidates for developing carcinoma of the lung,
although the evidence for this is currently speculative.
Former smokers have a fairly significant CEA titer
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elevation. Thirty percent of patients with nonmalignant disease may have a titer above 2.5 ng/ml, and
10% of these patients have a titer above 5 ng/ml.
However, the assay shows more frequent and more
marked elevation of the antigen titer in patients with
malignancy, especially colorectal carcinomas. Eighty
percent of patients with colorectal carcinoma have a
titer greater than 2.5 ng/ml. Fifty percent have a titer
above 5 ng/ml. Other tumors such as lung carcinoma
are also associated with a high incidence of elevated
titer.
An early criticism of the CEA assay was the high
incidence of false-negative results in patients with
early-stage colonic carcinomas. The five-year survival
statistics for treated patients with Duke's stage A
colonic carcinoma is almost 100%. In the stage B
group, the survival is approximately 50% to 60%, and
in the stage C group (those patients in whom the
tumor has gone through the serosa and actually
metastasized to local nodes), the survival drops to
only about 25% at five years. Ideally, we would prefer
an assay that would detect 100% of patients with
colonic carcinoma, Duke's stage A (assuming that
most of these tumors do go through a progression
from stages A to C). However, using the current CEA
assay, only 20% of patients with stage A lesions will
have an elevated titer. In other words, 80% of the
patients with this type of lesion will have a normal
CEA titer. About 40% to 50% of patients with stage B
lesions will have positive titers. It is only when the lesion actually breaks through the serosa and is involving local nodes that the probability of an elevated
CEA titer approaches 90% to 100%. Therefore, the
current CEA immunoassay cannot be used alone as a
cancer-screening study. Its value in screening
patients, however, should not be totally discounted
since there is a significant five-year survival in treated
patients even in the stage B and C categories.
Doctor William McCartney, Mrs. Erika Lawrence,
and I performed a study at the University of Chicago,
comparing the relative value of the CEA titer to the
conventional colon examination for the diagnosis of
carcinoma of the colon (3). The study included almost
1,000 patients who were referred for radiologic colon
examination . Carcinoembryonic antigen titer above 3
ng/ ml (a level we arbitrarily selected to divide the
normal from abnormal groups) was detected in 15%
of patients subsequently diagnosed as normal, or
having inactive inflammatory bowel disease. There
was a 30% incidence of elevated titers in patients who
had cirrhosis and noncolonic malignancies. Less than
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10% of the patients with benign colonic polyps in this
series had significant titer elevation.
By comparison, the conventional radiologic colon
examination was positive, that is, showed evidence
for malignancy in only 10 out of 850 patients who
were subsequently established not to have colonic
malignancy. The colon examination was, therefore,
much more specific for excluding the diagnosis of carcinoma of the colon in patients subsequently proven
not to have colonic maiignancy.
Forty-eight of the patients in this series were subsequently proven to have carcinoma of the colon, first
diagnosed at the time of the study. The CEA titer was
normal in 16 of these patients and was abnormal in
only 67%, whereas the conventional radiologic colon
examination was abnormal in 90% of these patients.
The radiologic colon examination was, therefore,
clearly superior to the CEA test for detection of new
carcinomas of the colon. However, there were three
patients with carcinoma of the colon in this study in
whom the radiologic colon examination was originally considered to be normal or show signs representing
benign disease, who did have elevated CEA titers.
The CEA titer was potentially helpful in these cases
in raising the suspicion of colonic carcinoma. If the
results of the two tests are combined, the accuracy of
the diagnosis is 96%, which represents some improvement over the radiologic colon examination alone.
In active ulcerative colitis, the CEA level is frequently elevated and the level itself is not a useful clue
to detect early development of malignancy. The
patients with quiescent bowel disease usually have
normal titers. In a patient with quiescent bowel disease, a rising CEA titer should be treated with great
suspicion for neoplasm.
Although the radiologic colon examination is
clearly superior for the initial diagnosis of colonic
malignancy, the CEA titer is equally superior for the
diagnosis of recurrence of colonic carcinoma. In our
studies of patients with recurrent colonic carcinoma,
only 2 of 15 patients with recurrence had a normal
CEA titer. The barium enema indicated recurrence in
only 3 of these 15 patients. The barium enema did
detect the two cases of recurrence with normal CEA
titers. Frequently, the recurrence of colonic carcinoma is not in the area of the primary tumor but
rather in the liver or.elsewhere in the body. It is also
very difficult to distinguish postoperative changes in
the bowel from early recurrence of tumor on a conventional radiologic colon examination. These factors probably account for the poor detection rate of

130

HOFFER: RADIOIMMUNOLOGIC METHODS FOR DIAGNOSIS

recurrence seen with the conventional radiologic
colon examination.
In summary, the CEA titer is not as sensitive as the
radiologic colon examination for the diagnosis of
primary carcinoma, but it is very useful in following
patients for recurrent carcinoma.
Another area of potential use for the CEA
radioimmunoassay is in the detection of metastatic
malignancy of noncolonic origin. The test is extremely useful when interpreted in conjunction with
other tests for metastatic disease. Doctor William
McCartney, Erika Lawrence, and I studied 368
patients who had both liver scans and CEA immunoassay (4). The liver scan is a useful test for the
detection of hepatic metastasis for many primary
malignancies; however, it has a 30% incidence of falsenegative results and a 10% to 20% incidence of falsepositive results. The false-positive cases are primarily
patients with other disorders such as cirrhosis, who
show lesions on the liver scan which closely mimic
metastatic tumor. In this study, we chose a level of 9
ng/ ml as a dividing line between a positive result for
metastatic tumor and negative evidence for
metastatic tumor. It should be noted that this level is
considerably higher than the level usually selected for
detecting carcinoma of the colon.
Neither the liver scan nor the CEA assay was
perfect in detecting hepatic metastasis. However,
when the results of both tests were positive, the
probability that the patient had metastasis was
almost I00%, and when both tests were negative, the
probability of hepatic metastasis dropped to I%. If
the liver scan only was positive, the probability of
metastasis dropped to 60%, and if the CEA titer only

was positive, that is, above 9 ng/ ml, the probability
of hepatic metastasis was only 30%. These results suggest an important role of the CEA titer in evaluating
the patients with many types of tumors other than
colonic malignancy.
The continuing clinical use of the CEA titer will
undoubtedly reveal many other situations in which
the study is valuable. It is certainly not a diagnostic
panacea, and the results must be interpreted with
considerable caution. However, I believe we can look
forward to an era of continued expansion in this type
of tumor radioimmunoassay. More specific assays for
colonic tumor are being developed and will undoubtedly become available in the future. I am equally confident that similar assay techniques will be
developed for other types of malignancies.
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